Cayuga Biotech is a startup company developing novel hemostatic drugs and devices to treat uncontrollable bleeding episodes. Cayuga Biotech has created CAY001, a systemic drug designed to target bleeding in patients on anti-platelet drugs to reduce blood loss and save lives. CAY001’s mechanism of action potentially gives it a better safety profile than current drugs on the market, a key competitive advantage.